Open access
Open access
Powered by Google Translator Translator

Cardiology (all articles)

[Preprint] Post-marketing active surveillance of myocarditis and pericarditis following vaccination with COVID-19 mRNA vaccines in persons aged 12-39 years in Italy.

9 Feb, 2022 | 10:08h | UTC

Post-marketing active surveillance of myocarditis and pericarditis following vaccination with COVID-19 mRNA vaccines in persons aged 12-39 years in Italy: a multi-database, self-controlled case series study -medRxiv

Related:

Myocarditis after BNT162b2 vaccination in Israeli adolescents.

Myocarditis cases reported after mRNA-Based COVID-19 vaccination in the US from December 2020 to August 2021.

A case-control study showed an increased risk of myocarditis after COVID-19 vaccination with a messenger RNA vaccine compared to an inactivated virus vaccine.

[Preprint] Risk of myocarditis following sequential COVID-19 vaccinations by age and sex.

Risks of myocarditis, pericarditis, and cardiac arrhythmias associated with COVID-19 vaccination vs. SARS-CoV-2 infection.

Case series with 139 adolescents and young adults with suspected myocarditis following mRNA vaccination showed most cases had a mild clinical course and rapid resolution of symptoms.

Heart-inflammation risk from Pfizer COVID vaccine is very low.

Large cohort study with over 2.5 million individuals showed the incidence of myocarditis after the Pfizer vaccine was 2.13 cases per 100,000 persons.

Study with over 5.1 million vaccinated individuals showed the incidence of myocarditis after the receipt of the Pfizer vaccine was low and more common after the second dose in young male recipients.

Large Observational study shows Pfizer Covid vaccine is mostly safe but is associated with increased risk of myocarditis, adenopathy, appendicitis, and herpes zoster.

 

Commentary on Twitter

 

Study suggests routine cardiac screening is not needed before return to play in junior competitive athletes with mild or asymptomatic SARS-CoV-2.

9 Feb, 2022 | 10:01h | UTC

SARS-CoV-2 infection and return to play in junior competitive athletes: is systematic cardiac screening needed? – British Journal of Sports Medicine

 

Review: Supraventricular arrhythmia in pregnancy.

9 Feb, 2022 | 08:38h | UTC

Supraventricular arrhythmia in pregnancy – Heart

 

M-A: Direct oral anticoagulants vs. warfarin in patients with atrial fibrillation.

9 Feb, 2022 | 08:29h | UTC

Direct Oral Anticoagulants versus Warfarin in Patients with Atrial Fibrillation: Patient-Level Network Meta-Analyses of Randomized Clinical Trials with Interaction Testing by Age and Sex – Circulation (link to abstract – $ for full-text)

 

M-A: Colchicine after percutaneous coronary intervention significantly reduces the risk of major adverse cardiovascular events in patients with symptomatic coronary artery disease.

9 Feb, 2022 | 08:25h | UTC

Colchicine for symptomatic coronary artery disease after percutaneous coronary intervention – openheart

Related:

Expert Analysis | Colchicine in acute coronary syndrome: when to commence?

M-A: Colchicine in patients with coronary artery disease – “colchicine reduces the risk of myocardial infarction and stroke, but has a higher rate of gastrointestinal upset with no influence on all‐cause mortality”.

Review: Colchicine and the heart.

M-A: Colchicine administration for percutaneous coronary intervention

M-A: Efficacy and safety of low-dose colchicine in patients with coronary disease

Meta-analysis: Colchicine reduces new cardiovascular events in patients with coronary artery disease

Expert analysis: Efficacy and safety of colchicine in patients with chronic stable coronary disease

#ESCCongress – [Abstract Only] Randomized trial: Colchicine in patients with chronic coronary disease

#ESCCongress – Randomized trial: Colchicine not beneficial for patients with acute coronary syndrome

#ESCCongress – Time-to-treatment initiation of colchicine and cardiovascular outcomes after myocardial infarction in the Colchicine Cardiovascular Outcomes Trial (COLCOT)

#AHA19 – [Abstract Only] Practice Changing? – Randomized Trial: Low-Dose Colchicine Improves Outcomes after Myocardial Infarction

Research: Colchicine Therapy and Plaque Stabilization in Patients With Acute Coronary Syndrome

 

Randomized crossover study shows regular use of Paracetamol increases systolic blood pressure by approximately 5 mm Hg when compared with placebo in hypertensive individuals.

8 Feb, 2022 | 10:11h | UTC

Regular Acetaminophen Use and Blood Pressure in People With Hypertension: The PATH-BP Trial – Circulation (link to abstract – $ for full-text)

Commentaries:

Regular paracetamol use linked to higher blood pressure, study finds – University of Edinburg

Expert reaction to study looking at regular, long-term paracetamol use and blood pressure, in people with high blood pressures – Science Media Centre

Blood pressure warning over long-term paracetamol use – BBC

 

COVID-19 infections increase risk of heart conditions up to a year later, study finds.

8 Feb, 2022 | 10:15h | UTC

News Release: COVID-19 infections increase risk of heart conditions up to a year later, study finds – Washington University in St. Louis

Original Study: Long-term cardiovascular outcomes of COVID-19 – Nature Medicine

 

Practice guidelines for office and out-of-office blood pressure measurement.

8 Feb, 2022 | 10:02h | UTC

2021 European Society of Hypertension practice guidelines for office and out-of-office blood pressure measurement – Journal of Hypertension

 

In patients taking anticoagulants (DOAC or Warfarin), a respiratory tract infection not treated with antibiotics is associated with a greater than twofold increase in the risk of bleeding during the next 0-14 days.

8 Feb, 2022 | 08:46h | UTC

Respiratory tract infection and risk of bleeding in oral anticoagulant users: self-controlled case series – The BMJ

 

Commentary on Twitter

 

Podcast: Palpitation Pearls.

8 Feb, 2022 | 08:34h | UTC

#320 Palpitations with Dr. Joshua Cooper – The Curbsiders

 

Review | AI and the cardiologist: when mind, heart and machine unite.

8 Feb, 2022 | 08:28h | UTC

AI and the cardiologist: when mind, heart and machine unite – OpenHeart

 

EULAR recommendations for cardiovascular risk management in rheumatic and musculoskeletal diseases, including systemic lupus erythematosus and antiphospholipid syndrome.

7 Feb, 2022 | 08:43h | UTC

EULAR recommendations for cardiovascular risk management in rheumatic and musculoskeletal diseases, including systemic lupus erythematosus and antiphospholipid syndrome – Annals of Rheumatic Diseases

 

ERC-ESICM guidelines on temperature control after cardiac arrest in adults.

7 Feb, 2022 | 08:44h | UTC

ERC-ESICM guidelines on temperature control after cardiac arrest in adults – Intensive Care Medicine (if the link is paywalled, try this one)

Related:

M-A: In comatose survivors of cardiac arrest, targeted hypothermia is not associated with improved survival or better neurological outcomes vs. targeted normothermia.

RCT: In comatose survivors of out-of-hospital cardiac arrest, there was no difference in mortality and neurologic outcomes with mild (target temperature of 34 °C) vs. moderate therapeutic hypothermia (target temperature of 31 °C).

M-A: Targeted temperature management following out-of-hospital cardiac arrest – “Routine use of moderate or deep hypothermia in comatose survivors of OHCA may potentially be associated with more harm than benefit”.

RCT: In patients with coma after out-of-hospital cardiac arrest, targeted hypothermia did not improve outcomes.

 

Commentary on Twitter

 

Patent Foramen Ovale (PFO) After Stroke: Meta-analysis suggests the application of a multivariable causal classification system may better distinguish patient subgroups who may benefit from PFO closure from those unlikely to receive benefit.

7 Feb, 2022 | 08:31h | UTC

Heterogeneity of Treatment Effects in an Analysis of Pooled Individual Patient Data From Randomized Trials of Device Closure of Patent Foramen Ovale After Stroke – JAMA (link to abstract – $ for full-text)

Commentary: Classification System May Identify Patients Likely to Benefit from PFO Closure – Physician’s Weekly

Related:

Management of the Patient With Patent Foramen Ovale in 2021: A Spectrum of Cases

Practice advisory update summary: Patent foramen ovale and secondary stroke prevention: Report of the Guideline Subcommittee of the American Academy of Neurology – Neurology

 

Commentary on Twitter

 

Review: Post-transplant cardiovascular disease.

7 Feb, 2022 | 08:20h | UTC

Post-Transplant Cardiovascular Disease – Clinical Journal of the American Society of Nephrology

 

Implementation of a pharmacist-to-dose direct oral anticoagulant (DOAC) protocol was associated with a 44% reduction in DOAC-related medication errors at an academic medical center.

7 Feb, 2022 | 08:10h | UTC

A pharmacist-to-dose direct oral anticoagulant protocol on medication errors at an academic medical center – Journal of the American College of Clinical Pharmacy (link to abstract – $ for full-text)

Commentary: Pharmacist-to-Dose DOAC Protocol Reduces Medication Errors – American College of Cardiology

 

Guideline: Management of hypertension and renin-angiotensin-aldosterone system blockade in adults with diabetic kidney disease.

4 Feb, 2022 | 08:49h | UTC

Management of hypertension and renin-angiotensin-aldosterone system blockade in adults with diabetic kidney disease: Association of British Clinical Diabetologists and the Renal Association UK guideline update 2021 – BMC Nephrology

 

Podcast: Infective Endocarditis Pearls.

4 Feb, 2022 | 08:27h | UTC

Infective Endocarditis Pearls – The Curbsiders

 

Thrombolytic use for STEMI: what ED clinicians should know.

4 Feb, 2022 | 08:23h | UTC

Thrombolytic Use for STEMI: What ED Clinicians Should Know – emDocs

 

Optimal Background Pharmacological Therapy for Heart Failure Patients in Clinical Trials: JACC Review Topic of the Week.

3 Feb, 2022 | 08:42h | UTC

Optimal Background Pharmacological Therapy for Heart Failure Patients in Clinical Trials: JACC Review Topic of the Week – Journal of the American College of Cardiology

 

Perspective: Avoidance of β-blockers in patients who use stimulants is not supported by good evidence.

2 Feb, 2022 | 08:39h | UTC

Avoidance of β-blockers in patients who use stimulants is not supported by good evidence – Canadian Medical Association Journal

 

Takotsubo Syndrome: A review of presentation, diagnosis and management.

2 Feb, 2022 | 08:25h | UTC

Takotsubo Syndrome: A Review of Presentation, Diagnosis and Management – Clinical Medicine Insights: Cardiology

Related:

Middle-aged and older women are being diagnosed with Takotsubo Syndrome more frequently, up to 10 times more often, than younger women or men of any age.

International Expert Consensus Document on Takotsubo Syndrome

International Registry: 16.6% of Patients with Takotsubo Syndrome Have Underlying Malignancy

Systematic Review: Long-Term Prognosis and Outcome Predictors in Takotsubo Syndrome

Cohort Study: Hospital Readmission Following Takotsubo Syndrome

 

Review: Prevention of atherosclerosis from childhood.

2 Feb, 2022 | 08:12h | UTC

Prevention of atherosclerosis from childhood – Nature Reviews Cardiology (if the link is paywalled, try this one)

 

SCAI SHOCK Cardiogenic Shock Classification Expert Consensus Update.

1 Feb, 2022 | 09:53h | UTC

SCAI SHOCK Stage Classification Expert Consensus Update: A Review and Incorporation of Validation Studies: This statement was endorsed by the American College of Cardiology (ACC), American College of Emergency Physicians (ACEP), American Heart Association (AHA), European Society of Cardiology (ESC) Association for Acute Cardiovascular Care (ACVC), International Society for Heart and Lung Transplantation (ISHLT), Society of Critical Care Medicine (SCCM), and Society of Thoracic Surgeons (STS) in December 2021 – JSCAI

News Release: SCAI releases updated expert consensus to SCAI SHOCK classification – Society for Cardiovascular Angiography and Interventions

Commentaries:

SCAI SHOCK: Update Refines Cardiogenic Shock Classification – TCTMD

SCAI Releases Updated Expert Consensus to SCAI SHOCK Classification – American College of Cardiology

 

Commentaries on Twitter

 

M-A: Vasopressin and glucocorticoids for in-hospital cardiac arrest.

1 Feb, 2022 | 08:43h | UTC

Vasopressin and glucocorticoids for in-hospital cardiac arrest: A systematic review and meta-analysis of individual participant data – Resuscitation

Related: RCT: Vasopressin + Methylprednisolone increase the likelihood of return of spontaneous circulation compared to placebo in patients with in-hospital cardiac arrest.

 

Commentary on Twitter

 

Stay Updated in Your Specialty

Telegram Channels
Free

WhatsApp alerts 10-day free trial

No spam, just news.